Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 1876 AL 1890

Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status

Swart T, Hurley MJ.

CNS Drugs. 2016 Dec;30(12):1127-1135. doi: 10.1007/s40263-016-0393-9.

Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline

Panisset M, Stril JL, Bélanger M, Lehoux G, Coffin D, Chouinard S.

Can J Neurol Sci. 2016 Nov;43(6):809-814. doi: 10.1017/cjn.2016.289.

Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements

Wang JY, Zhuang QQ, Zhu LB, Zhu H, Li T, Li R, Chen SF, Huang CP, Zhang X, Zhu JH.

Sci Rep. 2016 Nov 9;6:36669. doi: 10.1038/srep36669.

Solutions for improving communication with Parkinson's disease patients

Holtgraves T.

Neurodegener Dis Manag. 2016 Dec;6(6):449-452. doi: 10.2217/nmt-2016-0042. Epub 2016 Nov 9.

Prenatal diagnosis and genetic discoveries of an intracranial mixed neuronal-glial tumor: A case report and literature review

Sun L, Wu Q, Pei Y, Li J, Ye J, Zhi W, Liu Y, Zhang P.

Medicine (Baltimore). 2016 Nov;95(45):e5378. doi: 10.1097/MD.0000000000005378.

Magnesium in the CNS: recent advances and developments

Vink R.

Magnes Res. 2016 Mar 1;29(3):95-101. doi: 10.1684/mrh.2016.0408.

Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms

Mack JM, Schamne MG, Sampaio TB, Pértile RA, Fernandes PA, Markus RP, Prediger RD.

Oxid Med Cell Longev. 2016;2016:3472032. doi: 10.1155/2016/3472032. Epub 2016 Oct 18.

Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management

Samudra N, Patel N, Womack KB, Khemani P, Chitnis S.

Drugs Aging. 2016 Dec;33(12):855-863. doi: 10.1007/s40266-016-0416-8.

Defects in trafficking bridge Parkinson's disease pathology and genetics

Abeliovich A, Gitler AD.

Nature. 2016 Nov 10;539(7628):207-216. doi: 10.1038/nature20414.

Stem cells differentiation and probing their therapeutic applications in hematological disorders: a critical review

Ali F, Taresh S, Al-Nuzaily M, Mok PL, Ismail A, Ahmad S.

Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4390-4400.

c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease

Lindholm D, Pham DD, Cascone A, Eriksson O, Wennerberg K, Saarma M.

Front Aging Neurosci. 2016 Oct 26;8:254. doi: 10.3389/fnagi.2016.00254. eCollection 2016.

Neuroanatomical changes in Parkinson's disease in relation to cognition: An update

Prakash KG, Bannur BM, Chavan MD, Saniya K, Sailesh KS, Rajagopalan A.

J Adv Pharm Technol Res. 2016 Oct-Dec;7(4):123-126. doi: 10.4103/2231-4040.191416.

Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease

Doria M, Maugest L, Moreau T, Lizard G, Vejux A.

Free Radic Biol Med. 2016 Dec;101:393-400. doi: 10.1016/j.freeradbiomed.2016.10.008. Epub 2016 Nov 9.

Neuroprotective Effect of Several Phytochemicals and Its Potential Application in the Prevention of Neurodegenerative Diseases

Wang J, Song Y, Gao M, Bai X, Chen Z.

Geriatrics (Basel). 2016 Nov 12;1(4):29. doi: 10.3390/geriatrics1040029.

Parkinson's disease and solvents: Is there a causal link?

Reis J, Benbrick E, Bonneterre V, Spencer PS.

Rev Neurol (Paris). 2016 Dec;172(12):761-765. doi: 10.1016/j.neurol.2016.09.012. Epub 2016 Nov 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias